News for Krystal Biotech, Inc. (KRYS)

On May 16, 2025, Citigroup analyst Yigal Nochomovitz announced a revision in the price target for Krystal Biotech (KRYS). The price target has been lowered to $

Market Analysis by covering: Sarepta Therapeutics Inc, Lantheus Holdings Inc, Krystal Biotech Inc. Read 's Market Analysis on Investing.com

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where Krystal Biotech, Inc. (NASDAQ:KRYS) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology […]

On May 7, 2025, Chardan Capital analyst Geulah Livshits reaffirmed a "Buy" rating for Krystal Biotech (KRYS). The biopharmaceutical company continues to receive

Net Revenue: $88.2 million for Q1 2025, up 95% from the prior year.Gross Margin: Consistent at 94% in Q1 2025.Cost of Goods Sold: $5 million, compared to $2.4

May 06, 2025 / 12:30PM GMTOperator Thank you for standing by and welcome to the Krystal Biotech first-quarter 2025 earnings call.(Operator instructions) As a re

Explore how Krystal Biotech (KRYS) drives global growth with VYJUVEK, robust pipeline advancements, and strategic initiatives.

Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ETCompany ParticipantsStephane Paquette - VP, Corporate...

On May 6, 2025, Krystal Biotech (KRYS) received reaffirmation from HC Wainwright & Co., with analyst Joseph Pantginis reiterating a "Buy" rating for the company

Revenue: Achieved $88.2 million in net product revenue for Q1 2025, falling short of the estimated $96.24 million.Earnings Per Share (EPS): Reported EPS of $1.

**media[615863]**

**media[588445,588446]**

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Krystal Biotech (KRYS) has received a positive recommendation from EU regulators for its drug Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa.

Krystal Biotech Inc (KRYS), a commercial-stage biotechnology company, announced on February 28, 2025, that the European Medicines Agency's Committee for Medicin

EC approval decision anticipated in second quarter of 2025 PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the ”œCompany”) ( KRYS),

Summary Krystal Biotech Inc (KRYS), a commercial-stage biotechnology company, announced on February 26, 2025, that it will participate in the TD Cowen 45th Annu